"Non metastatic cancer" trang 1 - tải miễn phí từ tailieunhanh
Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: A meta-analysis and systematic review

Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: A meta-analysis and systematic review
13    70    1
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
8    56    1
Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer

Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer
9    58    1
Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: A 16-year retrospective review at the Douala general hospital, Cameroon

Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: A 16-year retrospective review at the Douala general hospital, Cameroon
9    60    1
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
9    58    1
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
5    70    0
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
9    63    0
Smoking cessation and survival among people diagnosed with non-metastatic cancer

Smoking cessation and survival among people diagnosed with non-metastatic cancer
9    36    1
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
10    59    1
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: Final results from phase II AIO KRK 0105 trial

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: Final results from phase II AIO KRK 0105 trial
7    46    1
Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
10    13    1
Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: A secondary analysis of the QUINTETT randomized trial

Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: A secondary analysis of the QUINTETT randomized trial
10    19    1
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study

Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study
8    39    1
A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer

A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer
12    21    1
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial
7    72    1
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: Result of an institution database from South Korea

Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: Result of an institution database from South Korea
8    46    1
Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells

Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells
24    80    1
Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: A retrospective study

Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: A retrospective study
9    45    1
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: The MOIO protocol study

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: The MOIO protocol study
10    6    1
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
4    74    1